Thermo Fisher Scientific Releases New Biopharmaceutical Characterization Technology
The company showcased new technologies at ASMS for biopharmaceutical characterization.
Thermo Fisher Scientific released new technologies for biopharmaceutical characterization at the American Society for Mass Spectrometry Conference (ASMS) in Texas, the company said in a press announcement. One of the featured products included Thermo Scientific’s Q Exactive BioPharma MS/MS Hybrid Quadropole-Orbitrap mass spectrometer. The spectrometer uses high-resolution, accurate-mass (HRAM) capabilities of the Orbitrap mass analyzer to enable key workflows for protein characterization in a single instrument. Combined with recommended sample preparation and analysis methods using Thermo Scientific reagents, columns, ultra high-pressure liquid chromatography (UHPLC) and data processing technologies, the Q Exactive BioPharma system provides a comprehensive solution for biopharmaceutical characterization. The company also showcased its new workflow driven software and cloud solutions to allow users to analyze insights in several applications, including proteomics, metabolomics, food safety, and biopharmaceutical characterization.
Source: Thermo Fisher Scientific
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
